Patent

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Retrieved on: 
Thursday, April 4, 2024
Depression, Brain, Patent, Patient, Anxiety, Electrode, ADI, Privacy

HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No.

Key Points: 
  • HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No.
  • The newly issued patent, entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia (ADI),” covers the method of use utilized in the Company’s Gen-3 HALO Clarity™ system.
  • Mark White, CEO of Nexalin Technology, stated, “This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology.
  • The Company’s technology uses a digital breakthrough in electrical waveforms to provide deep and painless brain neural stimulation.

SKYX Announces Issuance of 8 Additional New Patents in the U.S. and International including China, Europe and 2 Patents in India, for its Advanced, Smart Home and AI Platform Technologies

Retrieved on: 
Thursday, April 4, 2024
Patent, Lighting, AI

MIAMI, April 04, 2024 (GLOBE NEWSWIRE) -- SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 90 issued and pending patents in US and globally, and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, announced today the issuance of 8 additional new patents in the U.S. and internationally including China, Europe and 2 patents in India, for its advanced and smart platform technologies.

Key Points: 
  • The 8 additional patent issuances cover SKYX’s advanced plug and play and smart home platform technologies, enabling the usage of smart home and AI sensors in addition to home safety sensors.
  • This brings the Company’s intellectual property portfolio to a total of over 90 issued and pending patents, 30 of which are issued patents covering SKYX’s advanced plug and play and smart home platform technologies for the smart home, AI, electrical, and lighting industries.
  • These advancements position SKYX to be a leading technology provider of smart home platforms for the smart home, electrical and lighting industries.
  • Taken together, we are well positioned to create sustainable value for our shareholders over the long-term.”

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Retrieved on: 
Thursday, April 4, 2024
Plaintiff, Patent, District court, COVID-19, CFBV, Arbutus, Sale, Messenger, Moderna, Virology, Interim, Court, LNP

8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.

Key Points: 
  • 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
  • The following summarizes the Court’s Opinion:
    The Court agreed with Plaintiffs’ position that the claimed molar percentage (mol.
  • %) ranges can be met by any particle and is not limited to “finished” particles that are not subjected to further process steps.
  • “We are pleased with how the Court construed the disputed claim terms,” said Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, April 4, 2024
Research, Virtual, NSCLC, Immunotherapy, TIL, Patient, G&A, Allele, ACHL, HLA, Neoplasm, Therapy, Event, Safety, Melanoma, Patent, Escape Room, Cryptocurrency

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Key Points: 
  • These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
  • Research and development (R&D) expenses: R&D expenses were $15.9 million for the fourth quarter ended December 31, 2023, a decrease of $3.0 million compared to $18.9 million for the fourth quarter ended December 31, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $3.6 million for the fourth quarter ended December 31, 2023, a decrease of $0.4 million compared to $4.0 million for December 31, 2022.
  • Net loss: Net loss for the fourth quarter ended December 31, 2023 was $18.6 million or $0.46 per share compared to $24.1 million or $0.61 per share for the fourth quarter ended December 31, 2022.

Medigene AG Secures European Patent for its iM-TCR Technology

Retrieved on: 
Thursday, April 4, 2024
TCR, Patent, CSO, Research, Cell death, European Patent Convention, Safety

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies.
  • “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage.
  • Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research and experience.
  • We are pleased to receive this latest patent grant for our iM-TCR technology from the European Patent Office, which complements our recently granted patent in Japan,” said Dolores Schendel, CSO at Medigene.

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

Retrieved on: 
Wednesday, April 3, 2024
Depression, Neurology, Schizophrenia, Patent, CFO, Opioid use disorder, OTCQB

The USPTO has issued U.S. Patent No.

Key Points: 
  • The USPTO has issued U.S. Patent No.
  • 11,793,801 entitled, “Treatment of Pain and Neurological Conditions”.
  • The patent is directed towards the use of a compound and composition and/or dosage form for treating pain, depression, and schizophrenia.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented, “The patented invention may offer a novel approach to reducing the severity of withdrawal symptoms for opioid use disorder compared to current standards of care."

Becklar Patents AI-Powered Engage Platform to Accelerate Decision Making in the Moments that Matter

Retrieved on: 
Wednesday, April 3, 2024
Emergency, Health, Patient, AI, Human, AvantGuard, Patent, Machine learning

The newly patented Becklar Engage platform uses AI and machine learning to automatically determine the intent of incoming alarms, enabling live operators to focus on emergency signals and respond quickly in the moments that matter.

Key Points: 
  • The newly patented Becklar Engage platform uses AI and machine learning to automatically determine the intent of incoming alarms, enabling live operators to focus on emergency signals and respond quickly in the moments that matter.
  • Based on the success of the Engage platform for inbound calling, the Becklar AI Solutions Team has deployed the Engage platform for outbound customer engagement, scaling the technology beyond event response monitoring.
  • The AI platform is currently implemented across security, health and personal safety industries, as well as remote patient monitoring.
  • Becklar continues to be at the forefront of technology with the development and implementation of its AI-based Engage platform.

Perma-Fix Successfully Completes Pilot Plant Testing and Unveils New Process for Destruction of PFAS “Forever Chemicals”

Retrieved on: 
Wednesday, April 3, 2024
AFFF, Pregnancy, Centofanti, Obesity, Pressure, PFAS, Incineration, Environment, Cancer, Water pollution, Puberty, Risk, Calcium fluoride, Research, History, PESI, Fertility, Prostate, Commercial, Human, Chemistry, Infection, Ecosystem, Water, Kidney, Patent, Biosolids, Government, Cosmetics

Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.

Key Points: 
  • Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.
  • We expect that the Perma-Fix’s process will virtually eliminate PFAS compounds (minimum of 99.9999% destruction) and reduces the environmental liability associated with these materials.
  • Additionally, the process is designed to operate at a highly competitive price compared to traditional disposal options.
  • According to a recent article in Barron’s the estimated cleanup cost for PFAS compounds could exceed $200 billion.

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Retrieved on: 
Wednesday, April 3, 2024
Growth, Risk, Patient, EPO, European Patent Convention, Patent, Family, Professional corporation, SPCS, Triglyceride, Pharmaceutical industry

In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.

Key Points: 
  • In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
  • Additional independent patent applications from this family remain pending, which when granted, will further reinforce VAZKEPA’s exclusivity in Europe until April 2039.
  • Additionally, in November 2023, Amarin successfully defended a separate patent containing claims covering VAZKEPA in Europe from third-party opposition.
  • At the conclusion of that opposition, the EPO found all claims for Amarin’s 2033 VAZKEPA patent to be valid.